What is MIRCERA®?
MIRCERA® is a long-acting erythropoiesis-stimulating agent (ESA) used for the treatment of anemia associated with chronic kidney disease (CKD). Due to its specific mode of action, MIRCERA® allows correction of anemia and stable control of hemoglobin (Hb) levels at extended,
Safety and efficacy of every-two-week or once-monthly administration of MIRCERA® was confirmed in PROTOS clinical trial
Mean Monthly Hemoglobin Concentrations
(in the ITT population)
QW = once every week, Q2W = once every 2 weeks, Q4W = once every 4 weeks, TIW = 3 times weekly, SD = standard deviation, Hb = hemoglobin, BL = baseline, ITT population = intent-to-treat population
Sulowicz W, Locatelli F, Ryckelynck JP, et al. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly. Clin J Am Soc Nephrol. 2007;2(4):637-646.
For more information, please see the full Prescribing Information, including Boxed WARNING, and Medication Guide (English, Español) for MIRCERA®.
1Jarsch M, Brandt M, Lanzendörfer M, Haselbeck A. Comparative erythropoietin receptor binding kinetics of C.E.R.A. and epoetin-beta determined by surface plasmon resonance and competition binding assay. Pharmacology. 2008;81(1):63-9.
2MIRCERA® [prescribing information]. St. Gallen, Switzerland: Vifor (International) Inc.; June 2018.